Akademik Veri Yönetim Sistemi
Journal of Research in Pharmacy, cilt.30, sa.1, ss.28-38, 2026 (ESCI, Scopus, TRDizin)
Researchers have accelerated subject their research on platinum complexes since the serendipitous discovery of cisplatin's anticancer properties. Their goal is to synthesize more potent platinum complexes by replacing the carrier ammonia ligands in the structure of cisplatin with biologically active heterocyclic compounds. This approach is a key strategy for increasing the efficacy of cancer treatments and better targeting cancer types that develop resistance to current therapies. For this purpose, 1H-1,3-diazoles are heterocyclic compounds, well-known to biological systems and have exceptional pharmacological activities, were chosen carrier ligands in our study. In this paper, six novel platinum(II) complexes with the structures of [Pt(L1-3)2Cl2] (1a-c), and [Pt(L1-3)2I2] (2a-c), (L1= 1-(4-methoxyphenyl)-1H-1,3-diazole, L2= 1-phenyl-1H-1,3-diazole and L3= 1-benzyl-1H-1,3-diazole) were synthesized for cisplatin analogues. The chemical structures of 1a-c and 2a-c were elucidated by Fourier Transform Infrared (FT-IR), Proton Nuclear Magnetic Resonance (1H-NMR), Electrospray Ionization Mass Spectrometry (ESI-MS), and elemental analysis. The interactions of the complexes with pBR322 plasmid DNA and BamHI and HindIII restriction endonuclease enzymes were investigated by agarose gel electrophoresis. The cytotoxic effects of 1a-c and 2a-c against human non-small cell lung cancer (A549), human colon adenocarcinoma (CaCo-2), and mouse fibroblast cells (L929) cells were tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Compound 2c was as effective as cisplatin against the CaCo-2 cell line with 17.07 μM IC50 values.